Caligan Partners LP - 29 Jun 2023 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Reporting relationship: 10%+ Owner
Issuer ticker: LAB
Reported as of: 29 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2023, 17:18:05 UTC
Prior SEC filing: 30 Dec 2022
Next SEC filing: 11 Aug 2023
Source filing: View source filing
Reporting owner signature: Caligan Partners LP, By: /s/ David Edward Johnson, Partner

Key filing fact

Caligan Partners LP filed Form 4 for STANDARD BIOTOOLS INC. (LAB) on 03 Jul 2023.

Key facts

This page summarizes Caligan Partners LP's Form 4 filing for STANDARD BIOTOOLS INC. (LAB).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2023, 17:18.

Change

Previous filing in this sequence was filed on 30 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LAB transaction

Common Stock, $0.001 par value per share ("Common Stock")

Other

Transaction value
Shares: -108,879
Change %: -1.3%
Price
Shares after: 8,467,920
Date: 29 Jun 2023
Ownership: See footnote
Footnotes: F1, F2

LAB transaction

Common Stock

Other

Transaction value
Shares: -670,466
Change %: -7.9%
Price
Shares after: 7,797,454
Date: 03 Jul 2023
Ownership: See footnote
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

Footnote F2

The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

Footnote F3

This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

SEC remarks

The Reporting Persons disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of his or its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that any of the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 or for any other purpose.